Comparative Effectiveness Research
Costs and Effectiveness of Neonatal Male Circumcision

Seema Kacker, BS; Kevin D. Frick, PhD; Charlotte A. Gaydos, DrPH; Aaron A. R. Tobian, MD, PhD

Objective: To evaluate the expected change in the prevalence of male circumcision (MC)—reduced infections and resulting health care costs associated with continued decreases in MC rates. During the past 20 years, MC rates have declined from 79% to 55%, alongside reduced insurance coverage.

Design: We used Markov-based Monte Carlo simulations to track men and women throughout their lifetimes as they experienced MC procedure-related events and MC-reduced infections and accumulated associated costs. One-way and probabilistic sensitivity analyses were used to evaluate the impact of uncertainty.

Setting: United States.

Participants: Birth cohort of men and women.

Intervention: Decreased MC rates (10% reflects the MC rate in Europe, where insurance coverage is limited).

Outcomes Measured: Lifetime direct medical cost (2011 US$) and prevalence of MC-reduced infections.

Results: Reducing the MC rate to 10% will increase lifetime health care costs by $407 per male and $43 per female. Net expenditure per annual birth cohort (including procedure and complication costs) is expected to increase by $505 million, reflecting an increase of $313 per forgone MC. Over 10 annual cohorts, net present value of additional costs would exceed $4.4 billion. Lifetime prevalence of human immunodeficiency virus infection among males is expected to increase by 12.2% (4843 cases), high- and low-risk human papillomavirus by 29.1% (57124 cases), herpes simplex virus type 2 by 19.8% (124767 cases), and infant urinary tract infections by 211.8% (26876 cases). Among females, lifetime prevalence of bacterial vaginosis is expected to increase by 51.2% (538865 cases), trichomoniasis by 51.2% (64585 cases), high-risk human papillomavirus by 18.3% (33148 cases), and low-risk human papillomavirus by 12.9% (25837 cases). Increased prevalence of human immunodeficiency virus infection among males represents 78.9% of increased expenses.

Conclusion: Continued decreases in MC rates are associated with increased infection prevalence, thereby increasing medical expenditures for men and women.


State governments are increasingly eliminating Medicaid coverage for neonatal male circumcision (MC), with 18 states having abolished coverage.1 Meanwhile, the MC rate in the United States has decreased substantially.

For editorial comment see page 962

Although the prevalence of circumcision among men born in the 1970s and 1980s remained stable at approximately 79%,2,3 the MC rate decreased to 62.5% in 1999 and to 54.7% by 2010.4,5 Because Medicaid pays for more than one-third of all in-hospital MCs, further limitations to state coverage hinder access to MC and are likely to lead to further decreases.6,6 Private third-party payers are also decreasing coverage.4 Within Europe, where routine MC insurance coverage is rare, MC rates are 15.8% in the United Kingdom and 1.6% in Denmark.7,8 Male circumcision rate decreases have persisted despite growing evidence of medical benefit. Three randomized controlled trials in Africa demonstrated that MC was associated with a lowered risk of acquiring human immunodeficiency virus (HIV), low-risk and high-risk human papillomavirus (LR-HPV and HR-HPV, respectively), and herpes simplex virus type 2 (HSV-2).1,10-16 One of the trials also showed that female partners of circumcised men had a reduced risk of LR-HPV, HR-HPV, bacterial vaginosis (BV), and trichomoniasis.17,18 Observational stud-
ties of MC in the United States have demonstrated similar results, suggesting that efficacy estimates from the African trials are applicable to the United States. Furthermore, observational studies and meta-analyses have suggested that MC also offers a protective benefit against infant male urinary tract infections (UTIs).

Each year, sexually transmitted infections (STIs) in the United States cause substantial morbidity and mortality and cost an estimated $16.9 billion in direct medical costs alone. A comprehensive cost analysis of MC, incorporating recent randomized trial data on protection against multiple STIs, has not been conducted but is essential for guiding health care policy.

**METHODS**

A Markov-based Monte Carlo simulation model was constructed using TreeAge Pro Suite 2012 (TreeAge Inc) to estimate the change in lifetime costs and infection prevalence associated with decreasing MC rates in the United States, incorporating risks from all health conditions demonstrated to be significantly reduced by MC. Individual men and women of a birth cohort were observed throughout their lifetimes as they experienced potential MC procedure-related events and MC-reduced infections and accumulated associated costs.

Each potential health condition was modeled as a Markov state, and transition probabilities between states were defined using published incidence estimates and preventative efficacy from MC trial and meta-analysis data. Among males, MC procedure-related events included the procedure and possible complications, and MC-reduced infections included infant UTIs, HIV, HSV-2, HR-HPV, and LR-HPV. Male circumcision-reduced infections among females, incorporated in a separate Markov process, included BV, trichomoniasis, HR-HPV, and LR-HPV. Females did not experience MC procedure-related events but instead experienced protective benefits of MC through their association with circumcised males. The model (Figure, A) compared cost and infection outcomes for an individual within a “current context” strategy to the expected outcomes within a “policy change” strategy, characterized by lower MC rates. The MC rate under the current context strategy (79%) reflected characteristics of current adult men who were born before the rate decrease during the past 20 years and who are currently experiencing risks from MC-reduced STIs. The impact of uncertainty in input parameters, including cost, incidence, and preventative efficacy, was assessed using univariate and probabilistic sensitivity analyses.

A societal perspective was adopted and future costs were discounted to birth year by 3% annually. Only direct medical expenses were included, and cost parameters were adjusted to 2011 US$ using the medical care component of the Consumer Price Index.

**THE MODEL**

The individual microsimulation captured MC procedure-related events and MC-reduced infections through a series of 1-year cycles, beginning at birth. Because incidence data were unavailable or negligible for individuals aged 1 to 12 years, potential infections during this period were excluded. During each cycle, individuals faced age- and sex-specific risks from background mortality as well as risks from single or concurrent infections. As they acquired health conditions, individuals transitioned to corresponding Markov states and accumulated associated costs (Figure, B). The probability of transitioning to a health state depended on annual incidence and MC preventative efficacy for the infection(s). All individuals began in a “disease-free” state. During each 1-year cycle of the simulation, individuals may remain in their current state or transition to another possible state, acquiring a single infection or multiple infections at once. HIV indicates human immunodeficiency virus; HR-HPV, high-risk human papillomavirus; HSV-2, herpes simplex virus type 2; LR-HPV, low-risk human papillomavirus; pCirc, probability of MC protection under the given strategy; trich, trichomoniasis. *Infant male urinary tract infections and female bacterial vaginosis were incorporated but not modeled as separate Markov states.
under each strategy, the portion of males (or females) running through each subtree was defined by the MC rate.

Male circumcision procedure-related events and MC-reduced infections occurring only in the first year after birth—the procedure, potential complications,\textsuperscript{24,31} and infant male UTIs\textsuperscript{23}—were modeled as nonrecurrent risks, and associated costs accounted for a combination of individuals at high and low risk of STIs.

Under a no-MC Markov subtree, incidence of MC-reduced infections among males described the annual acquisition rate among susceptible uncircumcised men, and the incidence of MC-reduced infections among females described the annual acquisition rate among susceptible women associating with uncircumcised men. Similarly, incidence under an MC subtree reflected characteristics of circumcised males or among females associating with circumcised men. Because published incidence rates incorporated benefits of MC at the current level, incidence under a no-MC subtree was derived as follows: where

\[
Incidence = (Incidence|MC) × pMC + (Incidence|No MC) \times (1 - pMC)
\]

\[
(Incidence|MC) = (Incidence|No MC) \times MC\_Effect,
\]

\text{"pMC" was the MC rate, "(Incidence|MC)" indicated "Incidence\" conditional on MC status, and "MC\_Effect" was defined as incidence rate ratio (IRR) for the infection.}

Incidence rate ratios for STIs were drawn from random- ized trials following heterosexual males and female partners in Rakai, Uganda, and were based on an intention-to-treat analysis.\textsuperscript{1,14,15,17,18} Although 2 additional trials were conducted, only the Ugandan trial reported conservative efficacy estimates and was the only trial to evaluate female partners.\textsuperscript{1,17,21} Observa-

\begin{table}[h]
\centering
\caption{Model Parameters: Base-Case Values and Ranges for Sensitivity Analysis\textsuperscript{a}}
\begin{tabular}{|l|c|c|c|}
\hline
\textbf{Input Parameter} & \textbf{Base-Case (Range)} & \textbf{Source} \\
\hline
\hline
\multicolumn{3}{|l|}{Infant male, ages birth-1 y} \vspace{0.1cm} \\
Circumcision & & \\
Current rate, %, adult men in United States & 79 (60-80) & Xu et al\textsuperscript{2}, Sansom et al\textsuperscript{1} \\
Decreased rate, %, in Europe, without insurance coverage & 10 & Dave et al\textsuperscript{1}, Frisch et al\textsuperscript{1}, WHO\textsuperscript{1} \\
Procedure cost, $ & 291 (146-437) & Sansom et al\textsuperscript{2}, CDC\textsuperscript{1} \\
Complication rate, % & 0.4 (0.2-0.6) & CDC,\textsuperscript{2} AAP,\textsuperscript{1,25} Weiss et al\textsuperscript{23} \\
Complication cost, $ & 185 (130-235) & Schoen et al\textsuperscript{23} \\
Infant male urinary tract infection & & \\
Incidence, uncircumcised, % & 2.15 (1.9-2.4) & Schoen et al\textsuperscript{23} \\
Cost, uncircumcised, $ & 2055 (1541-2569) & Schoen et al\textsuperscript{23} \\
Cost, circumcised, $ & 1225 (919-1531) & Schoen et al\textsuperscript{23} \\
MC efficacy & 0.10 (0.08-0.12) & Schoen et al\textsuperscript{23} \\
\hline
\multicolumn{3}{|l|}{Adult male, ages 13-100 y} \vspace{0.1cm} \\
HIV & & \\
Incidence, ages 13-29 y, per 100 000 & 39.9 & CDC\textsuperscript{23} \\
Incidence, ages 30-39 y, per 100 000 & 64.1 & CDC\textsuperscript{23} \\
Incidence, ages 40-49 y, per 100 000 & 45.3 & CDC\textsuperscript{23} \\
Incidence, ages $\geq$50 y, per 100 000 & 10.2 & CDC\textsuperscript{23} \\
Portion due to heterosexual transmission (%) & 15.7 (6-20) & Sansom et al\textsuperscript{2}, CDC\textsuperscript{33} \\
Life expectancy posttreatment & 24.2 (22.0-26.0) & Schackman et al\textsuperscript{24}, Harrison et al\textsuperscript{25} \\
Lifetime cost, $ & 388 754 (29 565-485 942) & Schackman et al\textsuperscript{24}, Hutchinson et al\textsuperscript{26}, Chen et al\textsuperscript{27} \\
MC efficacy & 0.49 (0.29-0.81) & Gray et al\textsuperscript{23} \\
HPV & & \\
HPV incidence, per 100 000, varies by age\textsuperscript{b,c} & 35.6-450.9 & Hernandez et al\textsuperscript{19}, Chesson et al\textsuperscript{29} \\
HPV lifetime cost per case, $, varies by age\textsuperscript{a,d} & 509-1307 & Chesson et al\textsuperscript{19}, Hu and Goldie\textsuperscript{24}, Kim and Goldie\textsuperscript{41} \\
HR-HPV MC efficacy & 0.67 (0.51-0.89) & Gray et al\textsuperscript{24}, Gray et al\textsuperscript{42} \\
LR-HPV MC efficacy\textsuperscript{a} & 0.67 (0.51-0.89) & Gray et al\textsuperscript{24}, Tobian et al\textsuperscript{15} \\
HSV-2 & & \\
Incidence, ages 13-19 y, per 100 000 & 770 & Armstrong et al\textsuperscript{43} \\
Incidence, ages 20-29 y, per 100 000 & 780 & Armstrong et al\textsuperscript{43} \\
Incidence, ages 30-39 y, per 100 000 & 146 & Armstrong et al\textsuperscript{43} \\
Incidence, ages 40-49 y, per 100 000 & 400 & Armstrong et al\textsuperscript{43} \\
Incidence, ages $\geq$50 y, per 100 000 & 260 & Armstrong et al\textsuperscript{43} \\
Lifetime cost, per seropositive case, $ & 779 (584-974) & Chesson et al\textsuperscript{44} \\
MC efficacy\textsuperscript{1} & 0.72 (0.56-0.92) & Tobian et al\textsuperscript{15} \\
\hline
\end{tabular}
\end{table}
### Table 1. Model Parameters: Base-Case Values and Ranges for Sensitivity Analysis

<table>
<thead>
<tr>
<th>Input Parameter</th>
<th>Base-Case (Range)</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adult female, ages 13-100 y</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HPV</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HR-HPV incidence, per 100,000, varies by age</td>
<td>0.485 (0.4-0.5)</td>
<td>Chesson et al23</td>
</tr>
<tr>
<td>HR-HPV lifetime cost, $, varies by age</td>
<td>0.34-203</td>
<td>Chesson et al23</td>
</tr>
<tr>
<td>HR-HPV MC efficacy</td>
<td>0.72 (0.62-0.93)</td>
<td>Wawer et al18</td>
</tr>
<tr>
<td>LR-HPV incidence, per 100,000, varies by age</td>
<td>0.558</td>
<td>Chesson et al23</td>
</tr>
<tr>
<td>LR-HPV lifetime cost, $</td>
<td>570 (380-634)</td>
<td>Kim and Goldie41</td>
</tr>
<tr>
<td>LR-HPV MC efficacy</td>
<td>0.83 (0.69-1.00)</td>
<td>Wawer et al18</td>
</tr>
<tr>
<td>BV</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prevalence among ages 14-49 y, %</td>
<td>29.2 (27.2-31.3)</td>
<td>Allsworth and Peipert65</td>
</tr>
<tr>
<td>Portion symptomatic, %</td>
<td>25 (15-42)</td>
<td>Allsworth and Peipert65</td>
</tr>
<tr>
<td>Median age at infection</td>
<td>30.2</td>
<td>Allsworth and Peipert65</td>
</tr>
<tr>
<td>Cost per case, $</td>
<td>83 (62-104)</td>
<td>Carr et al19</td>
</tr>
<tr>
<td>Portion of recurrent cases, %</td>
<td>60 (40-70)</td>
<td>Marrazzo,48 Bradshaw et al49</td>
</tr>
<tr>
<td>MC efficacy</td>
<td>0.60 (0.38-0.94)</td>
<td>Gray et al7</td>
</tr>
<tr>
<td>Trichomoniasis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incidence, symptomatic, ages 13-14, per 100,000</td>
<td>5</td>
<td>Owusu-Edusei et al50</td>
</tr>
<tr>
<td>Incidence, symptomatic, ages 15-24, per 100,000</td>
<td>130</td>
<td>Owusu-Edusei et al50</td>
</tr>
<tr>
<td>Incidence, symptomatic, ages 25-34, per 100,000</td>
<td>168</td>
<td>Owusu-Edusei et al50</td>
</tr>
<tr>
<td>Incidence, symptomatic, ages 35-64, per 100,000</td>
<td>92</td>
<td>Owusu-Edusei et al50</td>
</tr>
<tr>
<td>Lifetime cost, ages 13-14 y, $</td>
<td>111</td>
<td>Owusu-Edusei et al50</td>
</tr>
<tr>
<td>Lifetime cost, ages 15-24 y, $</td>
<td>175</td>
<td>Owusu-Edusei et al50</td>
</tr>
<tr>
<td>Lifetime cost, ages 25-34 y, $</td>
<td>168</td>
<td>Owusu-Edusei et al50</td>
</tr>
<tr>
<td>Lifetime cost, ages 35-64 y, $</td>
<td>130</td>
<td>Owusu-Edusei et al50</td>
</tr>
<tr>
<td>MC efficacy</td>
<td>0.52 (0.05-0.98)</td>
<td>Gray et al7</td>
</tr>
</tbody>
</table>

**Abbreviations:** AAP, American Academy of Pediatrics; BV, bacterial vaginosis; CDC, Centers for Disease Control and Prevention; HIV, human immunodeficiency virus; HPV, human papillomavirus; HR, high risk; HSV-2, herpes simplex virus type 2; LR, low risk; MC, male circumcision; WHO, World Health Organization.

- **a** All cost parameters include direct medical costs only and have been converted to 2011 US$. Incidence parameters are reported as annual rates. Where no upper age limit for incidence was provided, an upper limit was assumed, after which the incidence was modeled as a decreasing function toward zero. Efficacy estimates are expressed as incidence rate ratios and based on an intention-to-treat analysis.
- **b** LR-HPV incidence estimate for HPV among men includes incident cases of penile cancer and genital warts due to HPV. Overall incidence estimate for HR-HPV among women includes incident cases of cervical intraepithelial neoplasia (stages 1-3), cervical cancer, vulvar cancer, and vaginal cancer due to HPV.
- **c** MC efficacy for HR-HPV is assumed to be the same as the MC incident rate ratio for HR-HPV because the prevalence risk ratios were similar.
- **d** Efficacy value expressed as a hazard ratio.
- **e** Prevalence among ages 14-49 y, % 29.2 (27.2-31.3) Allsworth and Peipert65
- **f** Median age at infection, % 25 (15-42) Allsworth and Peipert65
- **g** Cost per case, $83 (62-104) Carr et al19
- **h** Portion of recurrent cases, % 60 (40-70) Marrazzo,48 Bradshaw et al49
- **i** MC efficacy, % 0.60 (0.38-0.94) Gray et al7
- **j** Lifetime cost calculated as the product of cost per case and number of expected cases.

Although MC status was explicitly modeled among males, the transmission dynamics leading to protective effects or potential infection among females was not detailed. Instead, females faced the same preventative effects from MC as female partners in the same preventative benefits from MC who have identified MC protective effects. The incidence at each age was assumed to be constant across each age interval with reported estimates and between ages 30 to 65 years, after which a decrease to an incidence of 0 at age 100 years was modeled. The portion of HIV due to heterosexual transmission was an average rate across ages.13 Because the MC effect on nonheterosexually transmitted HIV is unclear (ie, among men who have sex with men and injection drug users),15 no preventative efficacy was assumed for these cases. The probability of a male with MC of age i contracting HIV was:

\[
(p_{HIV}(MC)) = \frac{\text{Incidence}_{HIV} \times e^{\text{MC}}}{\text{Infection}_{HIV} \times \text{MC}} + \frac{\text{Incidence}_{HIV} \times e^{\text{MC}} \times \text{MC}}{\text{Infection}_{HIV} \times \text{MC}}
\]

where, 

©2012 American Medical Association. All rights reserved.
The expected change in expenditure per foregone MC procedure was calculated by dividing the difference in expected costs for the entire cohort between scenarios of the current MC rate (79%) and of a decreased rate (10%) by the difference in procedures between these scenarios. Lifetime infection prevalence was also evaluated under each MC rate strategy. The base-case was analyzed using 500,000 simulations. During probabilistic sensitivity analysis, 1,000 simulations of 10,000 individual trials each were run, sampling system-level parameters (costs, efficacy, and incidence) at the beginning of each simulation and individual-level parameters (sex, age at death, age at BV infection, and HIV-related mortality) at the beginning of each trial. One-way sensitivity analysis was run with 200,000 trials to explicitly test for changes in outcomes at extreme values of HIV and MC procedure costs.

Under the base-case scenario, reducing MC rates from the current levels among sexually active men to current levels in Europe (10%), where MC is not routinely covered by insurance, would increase lifetime direct medical costs of MC-reduced infections by $5407 for each male and $43 for each female (Table 2). These costs accumulate to almost $916 million for each annual birth cohort. After considering MC procedure and complication expenses, net health care costs would increase by more than $505 million, reflecting an increased expenditure of $313 per foregone MC procedure. This expenditure increase is driven primarily by male HIV (78.9%), infant male UTIs (6.3%), and female HR-HPV (6.8%) (Table 3). More modest decreases in the MC rate yielded similar lifetime cost and infection prevalence increases.

Lifetime infection prevalence of all MC-reduced infections increased under all decreased MC rate strategies compared with the current context strategy. Among males in a birth cohort of 4 million, cases of infant male UTIs increased by 26,876 (211.8%), HIV infections increased by 4843 (12.2%), HPV infections increased by 57,124 (29.1%), and HSV-2 infections increased by 124,767 (19.8%) under a 10% MC rate (Table 3). Among females, cases of BV increased by 538,865 (51.2%), trichomonas infections increased by 64,585 (51.2%), HR-HPV infections increased by 33,148 (18.3%), and LR-HPV infections increased by 25,837 (12.9%).

Probabilistic sensitivity analysis demonstrated that the increased prevalence and lifetime direct medical costs of MC-reduced infections persisted after accounting for uncertainty in cost, efficacy, and incidence parameters (Table 4). Univariate sensitivity analysis indicated that cost savings associated with increased MC coverage would persist while the cost of HIV treatment is greater than $120,000 to $125,000 and while the cost of the MC procedure is less than $640 to $660.

**Comment**

There are an estimated 19 million new STIs annually in the United States, which cost the health care system $17 billion each year in direct medical expenses. Therefore, methods to curb STI incidence have both substantial health benefit and financial impact on a strained health
care system. This model suggests that reducing MC rates to levels seen in countries where MC is not covered by insurance (10%) would lead to an expected increase in lifetime direct medical costs of $505 million annually. For each year that MC rates continue to approximate 50%, the US health care system can expect to pay $211 million more than it would have paid had MC rates remained at their levels during the 1980s. During a 10-year time span, these costs would accumulate to nearly $2 billion. In the event that MC rates were to decrease to 10%, net present value of additional costs over 10 annual birth cohorts would need to exceed $4.4 billion.

To our knowledge, this study is the first to comprehensively analyze the cost and health impact of MC. All male and female STIs that have been shown through trials to be associated with MC were incorporated, as well as infant male UTIs, which have been well established by observational studies and meta-analyses to be partially averted by MC. Potential complications of the MC procedure were also considered.

Reversing MC rate trends may seem financially unappealing in the short run because cost savings from averted MC-reduced infections accumulate over a lifetime. However, more than 6% of savings, representing 14% of procedure cost, are experienced in the same year as the procedure. The favorable economic evaluation in this study is supported by a cost-effectiveness analysis of MC in the United States that was limited to HIV acquisition among heterosexual men.

The model compared the prevalence of and expenditure on MC-reduced infections between the current environment and scenarios of reduced MC rates. Because

### Table 2. Base-Case Analysis: Expected Change in Lifetime Cost of MC Procedure-Related Events and MC-Reduced Infections

<table>
<thead>
<tr>
<th>Variable</th>
<th>79 (Current)</th>
<th>50</th>
<th>25</th>
<th>20</th>
<th>10</th>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Men</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost per individual, $a</td>
<td>3259</td>
<td>3345</td>
<td>3419</td>
<td>3437</td>
<td>3465</td>
<td>3494</td>
</tr>
<tr>
<td>Net increase in cost, $b</td>
<td>86</td>
<td>160</td>
<td>178</td>
<td>206</td>
<td>235</td>
<td></td>
</tr>
<tr>
<td>Increase in MC-reduced infection cost, $c</td>
<td>171</td>
<td>318</td>
<td>350</td>
<td>407</td>
<td>465</td>
<td></td>
</tr>
<tr>
<td><strong>Women</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost per individual, $a</td>
<td>222</td>
<td>240</td>
<td>256</td>
<td>259</td>
<td>265</td>
<td>272</td>
</tr>
<tr>
<td>Net increase in cost, $b</td>
<td>18</td>
<td>34</td>
<td>37</td>
<td>43</td>
<td>50</td>
<td></td>
</tr>
<tr>
<td>Annual birth cohort, 4 milliond</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total cost, $, millionsa</td>
<td>7083</td>
<td>7294</td>
<td>7477</td>
<td>7519</td>
<td>7588</td>
<td>7659</td>
</tr>
<tr>
<td>Net increase in cost, $, millionsb</td>
<td>211</td>
<td>394</td>
<td>436</td>
<td>505</td>
<td>576</td>
<td></td>
</tr>
<tr>
<td>Increase in MC-reduced infection cost, $, millionsc</td>
<td>384</td>
<td>715</td>
<td>787</td>
<td>916</td>
<td>1046</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviation: MC, male circumcision.

- Cost includes lifetime direct medical expenses for all MC procedure-related events and MC-reduced infections.
- Net increase in costs due to MC procedure-related events (procedure and complications) and MC-reduced infections, under each “policy change” strategy to the “current context” MC rate = 79% strategy.
- Increase in costs due only to MC-reduced infections, comparing outcome under each “policy change” strategy with the “current context” MC rate = 79% strategy.
- Assumes a sex distribution of 0.51 (male)/0.49 (female).

### Table 3. Base-Case Analysis: Increase in Lifetime Prevalence of MC-Reduced Infections in Annual Birth Cohort Compared With “Current Context” Strategy

<table>
<thead>
<tr>
<th>Variable</th>
<th>50</th>
<th>25</th>
<th>20</th>
<th>10</th>
<th>0</th>
<th>Total Cost Increase, %b</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male MC-reduced infections, entire birth cohort</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HIV (% increase)</td>
<td>2053</td>
<td>3768</td>
<td>4161</td>
<td>4843</td>
<td>5530</td>
<td>78.9</td>
</tr>
<tr>
<td>HPV (% increase)</td>
<td>24196</td>
<td>44717</td>
<td>48829</td>
<td>57124</td>
<td>65434</td>
<td>1.2</td>
</tr>
<tr>
<td>HSV-2 (% increase)</td>
<td>52416</td>
<td>97631</td>
<td>106621</td>
<td>124767</td>
<td>142792</td>
<td>4.5</td>
</tr>
<tr>
<td>Infant UTI (% increase)</td>
<td>11234</td>
<td>20937</td>
<td>22936</td>
<td>26876</td>
<td>30756</td>
<td>6.3</td>
</tr>
<tr>
<td>Female MC-reduced infections, entire birth cohort</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HR-HPV (% increase)</td>
<td>14084</td>
<td>26003</td>
<td>28290</td>
<td>33148</td>
<td>37976</td>
<td>6.8</td>
</tr>
<tr>
<td>LR-HPV (% increase)</td>
<td>10870</td>
<td>20278</td>
<td>22151</td>
<td>25837</td>
<td>29546</td>
<td>0.6</td>
</tr>
<tr>
<td>BV (% increase)</td>
<td>224572</td>
<td>421976</td>
<td>460219</td>
<td>538865</td>
<td>617306</td>
<td>1.4</td>
</tr>
<tr>
<td>Trichomoniasis (% increase)</td>
<td>27084</td>
<td>50541</td>
<td>55186</td>
<td>64585</td>
<td>73886</td>
<td>0.4</td>
</tr>
</tbody>
</table>

Abbreviations: BV, bacterial vaginosis; HIV, human immunodeficiency virus; HPV, human papillomavirus; HR, high risk; HSV-2, herpes simplex virus type 2; LR, low risk; MC, male circumcision; UTI, urinary tract infection.

- Assumes an annual birth cohort of 4 million, with a sex distribution of 0.51 (male)/0.49 (female). Increase in prevalence is measured using the “current context” MC rate = 79% strategy as a baseline.
- Represents percentage of total expected cost increase in expenses for MC-reduced infections attributable to the respective condition. Calculated as an average percentage across all calculated “policy change” strategies.
The large majority of men who are currently sexually active (and thus currently at risk of experiencing MC-reduced infections) are at least 20 years old, the baseline current context scenario evaluated was characterized by MC prevalence among these men (79%). The prevalence of MC has decreased dramatically in just the past 20 years, at a rate of approximately 1% per year. Although a 10% MC prevalence in the United States may not be likely in the short run, the MC rate in countries such as Denmark, which does not offer routine insurance coverage, is only 1.6%. Because future MC prevalence in the United States is unknown, the model also evaluated scenarios characterized by MC rates of 50%, 25%, 20%, 10%, and 0%.

This analysis has several limitations and likely results in a conservative estimate of lifetime cost increases associated with decreased MC rates. First, although the Markov-based model allowed for infection acquisition throughout each individual's lifetime, it did not incorporate transmission events or contextual changes in infection prevalence across the cohort or changes in cost values, which might have occurred during the simulation. This study also did not account for variation in incidence at the individual level due to risk-taking behavior or condom use but instead used average incidence rates across individuals and assumed that background characteristics were balanced across each strategy. Male circumcision has been shown to have even higher protective efficacy among high-risk individuals. It is also unlikely that MC would result in moral hazard, leading to decreased rates of other preventative behaviors, such as condom use. In addition, the model is limited by the Markovian assumption: transition probabilities depended on the present state but not on any of the previous states. However, this assumption was reasonable for the infections considered because one STI does not necessarily cause others.

This model examined the accumulated lifetime direct medical costs for a specific set of possible MC procedure-related events and MC-reduced infections, which represents a limited portion of all possible MC-related expenses. Although cost parameters incorporated the diagnosis and treatment of an MC-reduced condition for infected individuals, they did not include subsequent costs due to increased risks from other relevant conditions (birth complications, other STIs, etc.). Furthermore, an individual's infection may have caused externalities by placing susceptible individuals at even higher risk of acquisition, but these costs were not included. Finally, only direct medical costs were assessed, ignoring direct non-medical costs (e.g., patient transportation) and all indirect costs (e.g., patient and caregiver productivity loss). Previous study of the economic burden of HIV suggests that associated indirect costs may be more than 4 times
the total direct medical expenses. Thus, cost increase outcomes presented in this study are highly conservative. Although opponents of MC have suggested that it may cause pain, decreased sexual pleasure, impaired sexual function, and psychological consequences, these effects would be considered indirect nonmedical costs and were not considered in this analysis. Furthermore, postprocedure follow-up with trial participants and US studies have not supported the existence of these negative consequences.

This model analyzed a limited set of MC-reduced infections, focusing exclusively on infant male UTIs and conditions demonstrated through randomized trials to be associated with MC. Observational studies conducted in the United States suggest that MC may also decrease the risk of phimosis, gonorrhea, nongonococcal urethritis, chlamydia, and urogenital mycoplasma, but potential cost savings from averting these conditions was not incorporated. The trial efficacy parameters incorporated here are also likely to underestimate true risk reduction, as demonstrated by even higher (67%–73%) reductions in HIV infection during long-term follow-up of male MC trial participants. Although there are multiple factors that contribute to a nation’s MC rate, it is likely that reductions in insurance coverage play a role in lowered MC rates. Thus, the financial and health implications of policies that affect MC are substantial. Furthermore, a closer examination of MC rates, STI incidence, and the demographic characteristics of Medicaid beneficiaries suggests that the subpopulations likely to qualify for Medicaid also have the lowest rates of MC and the highest infection incidence. Therefore, decreased Medicaid coverage of MC may further exaggerate racial and socioeconomic disparities. Although this analysis has not explicitly evaluated the impact of reduced MC rates on such disparities, predictions based on this model’s outcomes and the heterogeneous distribution of infection burden and MC prevalence are concerning, and further study may be warranted. It is imperative to consider these results and their implications in establishing future health care policies related to MC.

Accepted for Publication: May 19, 2012.

Published Online: August 20, 2012. doi:10.1001/archpediatrics.2012.1440

Correspondence: Aaron A. R. Tobian, MD, PhD, Department of Pathology, School of Medicine, Johns Hopkins University, Carnegie 437, 600 N Wolfe St, Baltimore, MD 21287 (atobian1@jhmi.edu).

Author Contributions: All authors had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Kacker, Frick, Gaydos, and Tobian. Acquisition of data: Kacker, Gaydos, and Tobian. Analysis and interpretation of data: Kacker, Frick, Gaydos, and Tobian. Drafting of the manuscript: Kacker, Gaydos, and Tobian. Critical revision of the manuscript for important intellectual content: Kacker, Frick, Gaydos, and Tobian. Statistical analysis: Kacker and Frick. Administrative, technical, and material support: Kacker, Gaydos, and Tobian. Study supervision: Tobian.

Financial Disclosure: None reported.

Funding/Support: Dr Tobian was supported by grant 1K23AI093152-01A1 from the National Institutes of Health and Doris Duke Charitable Foundation Clinical Scientist Development Award (#22006.02). Dr Gaydos was supported by grants HPTN U-01 A1066813 and U-54EB007958 from the National Institutes of Health.

REFERENCES


